MAPT and Alzheimer disease: Specifically, research has shown that clearance of Alzheimer’s disease biomarkers, including amyloid-beta plaques or tau proteins [24], takes place at an accelerated rate in the brain during sleep compared to wakefulness, and the rate of buildup of Alzheimer's disease biomarkers is greater during wakefulness than during sleep.